See more : Energizer Holdings, Inc. (ENR) Income Statement Analysis – Financial Results
Complete financial analysis of Day One Biopharmaceuticals, Inc. (DAWN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Day One Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Prism Software Corporation (PSWR) Income Statement Analysis – Financial Results
- FoxWayne Enterprises Acquisition Corp. (FOXW) Income Statement Analysis – Financial Results
- Shareholder Value Beteiligungen AG (SVE.DE) Income Statement Analysis – Financial Results
- MEGMILK SNOW BRAND Co.,Ltd. (2270.T) Income Statement Analysis – Financial Results
- CoBank, ACB (CBKPP) Income Statement Analysis – Financial Results
Day One Biopharmaceuticals, Inc. (DAWN)
About Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 383.00K | 531.00K | 199.00K | 155.00K | 0.00 |
| Gross Profit | -383.00K | -531.00K | -199.00K | -155.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 130.52M | 85.62M | 43.58M | 9.10M | 13.90M |
| General & Administrative | 75.54M | 61.29M | 29.16M | 4.68M | 1.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.54M | 61.29M | 29.16M | 4.68M | 1.01M |
| Other Expenses | 1.00 | -18.00K | -15.00K | -31.00K | -2.00K |
| Operating Expenses | 206.06M | 146.91M | 72.74M | 13.78M | 14.91M |
| Cost & Expenses | 206.06M | 146.91M | 72.74M | 13.78M | 14.91M |
| Interest Income | 17.19M | 4.75M | 4.00K | 30.00 | 2.08K |
| Interest Expense | 0.00 | 4.75M | 4.00K | 30.00K | 2.08M |
| Depreciation & Amortization | 383.00K | 531.00K | 199.00K | 155.00K | 14.91M |
| EBITDA | -206.06M | -141.65M | -72.56M | -43.66M | -2.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -206.06M | -146.91M | -72.74M | -13.78M | -14.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.15M | 4.73M | -11.00K | -30.06M | -2.08M |
| Income Before Tax | -188.92M | -142.18M | -72.75M | -43.84M | -16.98M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -10.01M | -2.31M | -3.34M | -2.27M |
| Net Income | -188.92M | -132.18M | -70.44M | -40.51M | -14.71M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| EPS Diluted | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| Weighted Avg Shares Out | 79.77M | 65.47M | 61.95M | 61.93M | 61.93M |
| Weighted Avg Shares Out (Dil) | 79.77M | 65.47M | 61.95M | 61.93M | 61.93M |
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Day One Biopharmaceuticals is a leader in pediatric oncology, with a focus on addressing the unmet needs of pediatric cancer patients. The company has a strong financial position, with enough cash to fund operations through 2026, and is progressing through...
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that...
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
NDA for tovorafenib in relapsed or progressive pLGG accepted for FDA priority review PDUFA target action date of April 30, 2024 BRISBANE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a...
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that...
Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch
Day One Biopharmaceuticals, Inc. is awaiting an FDA filing decision on its lead drug tovorafenib for the treatment of pediatric low grade glioma in mid-November of 2023. The company is also running a phase 3 study to evaluate tovorafenib as...
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA filing decision expected by mid-November BRISBANE, Calif., Sept....
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA filing decision expected by mid-November BRISBANE, Calif., Sept....
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma (RANO-HGG) evaluable patients presented at the 2023 American Society of Clinical Oncology (ASCO) Annual...
Diving Into Day One Biopharmaceuticals
Shares of precision oncology concern Day One Biopharmaceuticals, Inc. are down over 50% from their 2023 high as Novartis' combination therapy received first approval for pLGG. However, its lead candidate (tovorafenib) has the potential to treat all BRAF-mutated pLGG patients,...
Source: https://incomestatements.info
Category: Stock Reports